期刊文献+

多发性骨髓瘤患者13q14.3区域一个候选抑瘤基因MYETS1的克隆与序列分析(英文) 被引量:1

Molecular Cloning and Sequence Anal ysis of a Candidate Tumor Suppressor Gene MYETS1 on Chromosome 13q14.3 of Patients with Multiple My eloma
下载PDF
导出
摘要 为克隆位于多发性骨髓瘤(multiplemyeloma,MM)患者染色体13q14.2~13q21.1区域候选抑瘤基因,通过生物信息学分析获取疾病基因定位区域内代表新基因的ESTs,并运用半定量RT-PCR检测它们在正常人与MM患者骨髓组织中的表达水平,发现一条在MM患者骨髓组织中明显表达下调的EST(GenBank收录号:H86826).Northern印迹杂交显示H86826在骨髓组织中转录本大小为1.5kb.通过购买商品化克隆IM-AGE223589测序获得了H86826所代表的基因的1491bp全长cDNA序列(GenBank收录号:AY368652),人类基因组命名委员会将其命名为MYETS1(myelomatumorsuppressor1).生物信息学分析其为一个编码分子质量为15.1kD、等电点为6.13的135个氨基酸的新基因.该基因的功能正在进一步的研究之中. In order to clone the novel genes with in chromosome 13q14.2~13q21.1dele ted in multiple myeloma (MM)patients,the expressed sequence ta gs(ESTs )which represent the novel gene in thi s region were obtained by bioinformatics analysis,then its expression was detected by semi-quantitative reverse tran-scription -polymerase chain reaction(RT-PCR).A significantly low expression of EST H86826was shown in the bone marrows of MM patients as com pared with that of the normals.The tr anscriptional size of this gene was estimated to be around 1.5kb using northern blot hybridization.Finally full-length sequence of the gene was harvested by sequencing the commerc ial clone-IMAGE 223589that was searched by electronic hybridization.It represents a novel gene named as my eloma tumor suppressor 1(MYETS1)encoding a polypeptide of 135amino acids,with molecular weight o f 15.1kD and pI 6.13.The function of M YETS1will be investigated further.
出处 《生命科学研究》 CAS CSCD 2004年第3期264-271,共8页 Life Science Research
基金 国家自然科学基金资助项目(30270576) 湖南省杰出青年基金资助(04JJ1006)~~
关键词 多发性骨髓瘤 定位候选克隆 候选抑瘤基因 生物信息学分析 MYETSl multiple myeloma (MM) positional candidate cloning can didate tumor suppressor gene bioinformatics MYETS1
  • 相关文献

参考文献13

  • 1GADO K, DOMJAN G, HEGYESI H, et al. Role of Interleukin-6 in the pathogenesis of multiple myeloma [J]. Cell Biol Int, 2000, 24(4): 195-209.
  • 2SZCZEPEK A J, BELCH A R, PILARSKI L M. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cell in multiple myeloma: potential for autocrine and paracrine networks[J]. Exp Hematol, 2001, 29(9): 1076-1081.
  • 3JELINEK D F. Mechanisms of myeloma cell growth control [J].Hematol Oncol Clin North Am, 1999, 13(6): 1145-1157.
  • 4DRACH J, KAUFMANN, URBAUER E, et al. The biology of multiple myeloma [J]. J Cancer Res Clin Oncol, 2000, 126(8): 441-447.
  • 5BERNASCONI P, CAVIGLIANO P M, BONI M, et al.Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance[J].Br J Haematol, 2002, 118(2): 545-549.
  • 6AVET-LOISEAU H, FACON T, GROSBOIS B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q ehromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation[J]. Blood, 2002,99(6): 2185-2191.
  • 7WOREL N, GREINIX H, ACKERMANN J, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma [J]. Ann Hematol,2001, 80(6): 345-348.
  • 8SHAUGHNESSY J, TIAN E, SAWYER J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH [J]. Blood, 2000, 96(4):1505-1511.
  • 9FONSECA R, OKEN M M, HARRINGTON D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy [J]. Leukemia, 2001, 15(6): 981-986.
  • 10江宁,湛凤凰,谢奕,曾朝阳,周鸣,邓龙文,李桂源.构建7q32区域鼻咽癌和正常鼻咽上皮细胞部分基因的表达图谱[J].中华医学遗传学杂志,1998,15(5):267-270. 被引量:12

二级参考文献9

  • 1Ji H J,Cancer Res,1997年,57卷,3期,759页
  • 2Sun Y,Can J,1995年,8卷,6期,325页
  • 3陈孝光,中国科学技术协会中国科协首界青年学术论文集,1992年,48页
  • 4Yao K T,Int J Cancer,1992年,45卷,1期,83页
  • 5Liang P,Science,1992年,257卷,5072期,967页
  • 6Li G Y,Chin J Cancer Res,1991年,3卷,1期,31页
  • 7Zhang S Z,Hereditas,1982年,97卷,1期,23页
  • 8姚开泰,湖南医学院学报,1982年,7卷,1期,10页
  • 9邓龙文,姚开泰.人鼻咽上皮细胞株HNE-1染色体高分辨显带的研究[J].癌症,1993,12(4):271-273. 被引量:7

共引文献11

同被引文献14

  • 1Matsui W,Wang Q,Barber JP,et al.Clonogenic multiplemyeloma progenitors,stem cell properties,and drug resistance[J].Cancer Res,2008,68(1):190–197.
  • 2Vallet S,Raje N.Bone anabolic agents for the treatment ofmultiple myeloma[J].Cancer Microenviron,2011,4(3):339–349.
  • 3Schmidt-Wolf IG,Glasmacher A,Hahn-Ast C,et al.Chromosomalaberrations in 130 patients with multiple myeloma studied byinterphase FISH:diagnostic and prognostic relevance[J].CancerGenet Cytogenet,2006,167(10):20–25.
  • 4Takahashi K,Oka A,Mizuguchi M,et al.Interstitial deletion of13q14. 13–q32. 3 presenting with Arima syndrome and bilateralretinoblastoma[J].Brain Dev,2011,33(4):353–356.
  • 5Zojer N,K nigsberg R,Ackermann J,et al.Deletion of13q14 remains an independent adverse prognostic variablein multiple myeloma despite its frequent detectionby interphase fluorescence in situ hybridization[J].Blood,2000,95(6):1925–1930.
  • 6Sagaster V,Ludwig H,Zojer N,et al.Bortezomib in relapsedmultiple myeloma:response rates and duration of responseare independent of a chromosome 13q-deletion[J].Leukemia,2007,21(1):164–168.
  • 7Shaughnessy J,Tian E,Sawyer J,et al.High incidence ofchromosome 13 deletion in multiple myeloma detected bymultiprobe interphase FISH[J].Blood,2000,96(4):1505–1511.
  • 8Shaughnessy J,Tian E,Sawyer J,et al.Prognostic impact ofcytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma:earlyresults of total therapy II[J].Br J Haematol,2003,120(1):44–52.
  • 9Shaughnessy J,Haessler J,Rhee F,et al.Testing standard andgenetic parameters in 220 patients with multiple myeloma withcomplete data sets:superiority of molecular genetics[J].Br JHaematol,2007,137(6):530–536.
  • 10Elnenaei MO,Hamoudi RA,Swansbury J.Delineation of theminimal region of loss at 13q14 in multiple myeloma[J].GenesChromosome Cancer,2003,36(1):99–106.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部